The biopharmaceutical company Biopharma, the investement of Q Partners, begins to conduct EIA (enzyme immunoassay) tests for availability of COVID-19 antibody assay for all plasma donors, EIA testing will identify those who have the disease in a latent form.
“Biopharma purchased 12,000 EIA tests manufactured by Roche and on May 18 we will begin testing donors for antibodies on our hardware base,” Kostiantyn Yefymenko, the co-owner of the company, said on his Facebook page.
He recalled that Biopharma has begun collecting plasma from donors who have undergone COVID-19.
Biopharma has begun the development of a hyperimmune immunoglobulin based on plasma of people who had COVID-19, this drug can be effective for specific treatment of COVID-19.
Biopharma, the investement of Q Partners, is a Ukrainian biotechnology company, the only plant in Eastern Europe that has modern technology, has been manufacturing and developing drugs from donated plasma for almost 50 years.
2020.04.24
20, Dragomyrova Str. Kiyv, 01103, Ukraine
